NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT06601192,A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults,https://clinicaltrials.gov/study/NCT06601192,,RECRUITING,The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.,NO,RSV Infection|QTc Interval,DRUG: zelicapavir (therapeutic dose)|DRUG: zelicapavir (supratherapeutic dose)|DRUG: Placebo|DRUG: moxifloxacin,"Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of Zelicapavir, Up to 24 hours post dose","Time-matched, placebo-corrected, change-from-baseline non-QT intervals after TD and SD of Zelicapavir, Up to 24 hours post dose|Time-matched, placebo-corrected, change-from-baseline HR after TD and SD of Zelicapavir, Up to 24 hours post dose|Concentration-QTc analysis based on the relationship between plasma concentrations of zelicapavir and ΔΔQTcF after a TD and SD of zelicapavir, Up to 96 hours post dose|Cmax of zelicapavir, Up to 96 hours post dose|Tmax of zelicapavir, Up to 96 hours post dose|t1/2 of zelicapavir, Up to 96 hours post dose|Vd/F of zelicapavir, Up to 96 hours post dose|CL/F of zelicapavir, Up to 96 hours post dose|ΔΔQTcF after moxifloxacin dosing, Up to 24 hours post dose|Safety measured by adverse events, Up to Day 33",,"Enanta Pharmaceuticals, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1,72,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",EDP 938-008,2024-07-15,2025-02,2025-02,2024-09-19,,2024-10-24,"ICON, Lenexa, Kansas, 66219, United States|ICON Early Phase, LLC, San Antonio, Texas, 78290, United States",
